Trial of varenicline (Champix) for the treatment of spinocerebellar degeneratio

Phase 1

Recruiting

• Conditions: spinocerebellar degeneration (SCD)

• Registration Number: JPRN-UMIN000011560
• Lead Sponsor: iigata University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-08-26
• Study Completion: 2015-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1) any unstable illness or concomitant medical condition that precluded participation in this study, including other disorders that may affect gait or balance (stroke, arthritis, or others) 2) pregnancy or lactation 3) smoking at the time of screening or within the past 12 months 4) concurrent treatment with monoamine oxidase inhibitors, bupropion, or nicotine patches 5) dementia or other psychiatric illness (including psychosis, bipolar disorder, untreated depression (Beck Depression Inventory score 21), or history of suicide attempt) or any other illness that would have precluded a patient from giving informed consent (Mini-Mental State Examination score 24) 6) use of varenicline within the previous 30 days 7) ataxia derived from any cause other than genetically confirmed SCA and CCA (including but not limited to alcoholism, head injury, multiple sclerosis, and multiple system atrophy)

Study & Design

• Study Type: Interventional
• Study Design: Not specified